From Action to Awareness with Two Rare Disease Parents

The Foundation for Angelman Syndrome Therapeutics (FAST) has helped redefine the role of advocacy groups. Founded and led by parents, FAST has moved beyond raising awareness to actively fund, coordinate, and accelerate cutting-edge research and clinical development. Its venture-philanthropy model has helped de-risk early science and attract industry partners. FAST's Vice Chair Mike Hanrahan and Chief Scientific Officer Dr. Allyson Berent share their journey as parents and advocates.